Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular adenoma

Xianyin Lai, Shaoxiong Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but some adenomas have the potential to progress to follicular carcinoma. Therefore, it is important to monitor the state and progress of follicular adenoma in the clinic and discover drug development targets for the treatment of follicular adenoma to prevent its worsening to follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks applications of up-to-date technologies, including proteomics and bioinformatics. To discover novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare follicular adenoma with normal thyroid tissue samples. The proteomics analysis revealed 114 protein biomarker candidates out of 1,780 identified and quantified proteins. A comprehensive approach to prioritize the biomarker candidates by category and rank revealed CD63, DDB1, TYMP, VDAC2, and DCXR as the top five biomarker candidates. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) software discovered four therapeutic target candidates for follicular adenoma, including TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target candidates for a follow-up study, which will facilitate monitoring and treatment of follicular adenoma.

Original languageEnglish (US)
Pages (from-to)271-282
Number of pages12
JournalCancer Genomics and Proteomics
Volume12
Issue number6
StatePublished - Nov 1 2015

Fingerprint

Biomarkers
Adenoma
Proteomics
Therapeutics
Thyroid Gland
Proteins
Carcinoma
Liquid chromatography
Bioinformatics
Mass spectrometry
Tandem Mass Spectrometry
Computational Biology
Liquid Chromatography
Tissue
Software
Monitoring
Technology
Pharmaceutical Preparations

Keywords

  • Adenoma
  • Biomarker
  • Follicular
  • Mass spectrometry
  • Therapeutic target

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Biochemistry

Cite this

Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular adenoma. / Lai, Xianyin; Chen, Shaoxiong.

In: Cancer Genomics and Proteomics, Vol. 12, No. 6, 01.11.2015, p. 271-282.

Research output: Contribution to journalArticle

@article{2be929c4913f46c09f076510647885c6,
title = "Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular adenoma",
abstract = "Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but some adenomas have the potential to progress to follicular carcinoma. Therefore, it is important to monitor the state and progress of follicular adenoma in the clinic and discover drug development targets for the treatment of follicular adenoma to prevent its worsening to follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks applications of up-to-date technologies, including proteomics and bioinformatics. To discover novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare follicular adenoma with normal thyroid tissue samples. The proteomics analysis revealed 114 protein biomarker candidates out of 1,780 identified and quantified proteins. A comprehensive approach to prioritize the biomarker candidates by category and rank revealed CD63, DDB1, TYMP, VDAC2, and DCXR as the top five biomarker candidates. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) software discovered four therapeutic target candidates for follicular adenoma, including TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target candidates for a follow-up study, which will facilitate monitoring and treatment of follicular adenoma.",
keywords = "Adenoma, Biomarker, Follicular, Mass spectrometry, Therapeutic target",
author = "Xianyin Lai and Shaoxiong Chen",
year = "2015",
month = "11",
day = "1",
language = "English (US)",
volume = "12",
pages = "271--282",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular adenoma

AU - Lai, Xianyin

AU - Chen, Shaoxiong

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but some adenomas have the potential to progress to follicular carcinoma. Therefore, it is important to monitor the state and progress of follicular adenoma in the clinic and discover drug development targets for the treatment of follicular adenoma to prevent its worsening to follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks applications of up-to-date technologies, including proteomics and bioinformatics. To discover novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare follicular adenoma with normal thyroid tissue samples. The proteomics analysis revealed 114 protein biomarker candidates out of 1,780 identified and quantified proteins. A comprehensive approach to prioritize the biomarker candidates by category and rank revealed CD63, DDB1, TYMP, VDAC2, and DCXR as the top five biomarker candidates. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) software discovered four therapeutic target candidates for follicular adenoma, including TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target candidates for a follow-up study, which will facilitate monitoring and treatment of follicular adenoma.

AB - Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but some adenomas have the potential to progress to follicular carcinoma. Therefore, it is important to monitor the state and progress of follicular adenoma in the clinic and discover drug development targets for the treatment of follicular adenoma to prevent its worsening to follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks applications of up-to-date technologies, including proteomics and bioinformatics. To discover novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare follicular adenoma with normal thyroid tissue samples. The proteomics analysis revealed 114 protein biomarker candidates out of 1,780 identified and quantified proteins. A comprehensive approach to prioritize the biomarker candidates by category and rank revealed CD63, DDB1, TYMP, VDAC2, and DCXR as the top five biomarker candidates. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) software discovered four therapeutic target candidates for follicular adenoma, including TGFB1, MYC, ANGPT2, and NFE2L2. This study provided biomarker and therapeutic target candidates for a follow-up study, which will facilitate monitoring and treatment of follicular adenoma.

KW - Adenoma

KW - Biomarker

KW - Follicular

KW - Mass spectrometry

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=84948757171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948757171&partnerID=8YFLogxK

M3 - Article

C2 - 26543076

AN - SCOPUS:84948757171

VL - 12

SP - 271

EP - 282

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 6

ER -